World's Best Scientists 2026 revealed!
Gordon W. Dewald

Gordon W. Dewald

D-Index & Metrics

Genetics

D-Index
88
Citations
28234
World Ranking
1172
National Ranking
564

Medicine

D-Index
92
Citations
31600
World Ranking
11293
National Ranking
5795

Gordon W. Dewald publication distribution in Genetics in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Genetics in 2026. The highlighted bar marks where Gordon W. Dewald sits on this spectrum.

45–54 publications: 6 scientists 55–64 publications: 10 scientists 65–74 publications: 35 scientists 75–84 publications: 84 scientists 85–94 publications: 102 scientists 95–104 publications: 151 scientists 105–114 publications: 175 scientists 115–124 publications: 203 scientists 125–134 publications: 217 scientists 135–144 publications: 205 scientists 145–154 publications: 193 scientists 155–164 publications: 188 scientists 165–174 publications: 170 scientists 175–184 publications: 178 scientists 185–194 publications: 164 scientists 195–204 publications: 173 scientists 205–214 publications: 159 scientists 215–224 publications: 134 scientists 225–234 publications: 143 scientists 235–244 publications: 105 scientists 245–254 publications: 114 scientists 255–264 publications: 92 scientists 265–274 publications: 88 scientists 275–284 publications: 87 scientists 285–294 publications: 80 scientists 295–304 publications: 62 scientists 305–314 publications: 75 scientists 315–324 publications: 67 scientists 325–334 publications: 60 scientists 335–344 publications: 52 scientists 345–354 publications: 40 scientists 355–364 publications: 48 scientists 365–374 publications: 47 scientists 375–384 publications: 46 scientists 385–394 publications: 31 scientists 395–404 publications: 27 scientists 405–414 publications: 40 scientists 415–424 publications: 30 scientists 425–434 publications: 43 scientists 435–444 publications: 29 scientists 445–454 publications: 14 scientists 455–464 publications: 28 scientists 465–474 publications: 21 scientists 475–484 publications: 21 scientists 485–494 publications: 22 scientists 495–504 publications: 17 scientists 505–514 publications: 12 scientists 515–524 publications: 11 scientists 525–534 publications: 8 scientists 535–544 publications: 8 scientists 545–554 publications: 14 scientists 555–564 publications: 4 scientists 565–574 publications: 11 scientists 575–584 publications: 5 scientists 585–594 publications: 11 scientists 595–604 publications: 12 scientists 605–614 publications: 7 scientists 615–624 publications: 6 scientists 625–634 publications: 10 scientists 635–644 publications: 9 scientists 645–654 publications: 10 scientists 655–664 publications: 6 scientists 665–674 publications: 6 scientists 675–684 publications: 6 scientists 685–694 publications: 4 scientists 695–702 publications: 6 scientists 703+ publications: 100 scientists
45 publications 703+

This scientist: 301 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 703 publications or more.

Gordon W. Dewald D-index placement in Genetics in 2026

The chart shows the D-index (discipline H-index) distribution of Genetics scientists ranked by Research.com in 2026. The highlighted bar marks where Gordon W. Dewald sits on this spectrum.

40–41 D-Index: 24 scientists 42–43 D-Index: 52 scientists 44–45 D-Index: 84 scientists 46–47 D-Index: 112 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 141 scientists 52–53 D-Index: 143 scientists 54–55 D-Index: 145 scientists 56–57 D-Index: 179 scientists 58–59 D-Index: 162 scientists 60–61 D-Index: 175 scientists 62–63 D-Index: 191 scientists 64–65 D-Index: 172 scientists 66–67 D-Index: 184 scientists 68–69 D-Index: 164 scientists 70–71 D-Index: 158 scientists 72–73 D-Index: 150 scientists 74–75 D-Index: 136 scientists 76–77 D-Index: 127 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 111 scientists 82–83 D-Index: 110 scientists 84–85 D-Index: 110 scientists 86–87 D-Index: 84 scientists 88–89 D-Index: 102 scientists 90–91 D-Index: 66 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 70 scientists 96–97 D-Index: 54 scientists 98–99 D-Index: 60 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 55 scientists 104–105 D-Index: 45 scientists 106–107 D-Index: 42 scientists 108–109 D-Index: 28 scientists 110–111 D-Index: 39 scientists 112–113 D-Index: 25 scientists 114–115 D-Index: 31 scientists 116–117 D-Index: 29 scientists 118–119 D-Index: 34 scientists 120–121 D-Index: 29 scientists 122–123 D-Index: 29 scientists 124–125 D-Index: 18 scientists 126–127 D-Index: 27 scientists 128–129 D-Index: 22 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 11 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 12 scientists 138–139 D-Index: 21 scientists 140–141 D-Index: 4 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 14 scientists 146–147 D-Index: 6 scientists 148–149 D-Index: 10 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 9 scientists 154–155 D-Index: 8 scientists 156–157 D-Index: 8 scientists 158–159 D-Index: 9 scientists 160+ D-Index: 96 scientists
40 D-Index 160+

This scientist: 88 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 160 D-Index or more.

Overview

Gordon W. Dewald was a researcher affiliated with the Mayo Clinic in the United States. Their work focused primarily on various fields of medicine, with notable contributions in hematology, public health, environmental and occupational health, and pediatrics, perinatology, and child health.

Their research addressed key topics including:

  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Childhood Cancer Survivors' Quality of Life

Dewald's recent scholarly output included publications spanning hematologic disorders and leukemia risk assessment. Notable papers included:

  • "Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL", published in 2021 in Blood
  • "Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders", published in 2020 in UNC Libraries

Throughout their career, Dewald collaborated frequently with other researchers. Their common coauthors were:

  • Elisabeth Paietta
  • Kathryn G. Roberts
  • Victoria Wang
  • Zhaohui Gu
  • Georgina Buck

Their publications appeared predominantly in the venues Blood and UNC Libraries, with at least one contribution to each.

Best Publications

  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

    Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis

  • Anthracycline Dose Intensification in Acute Myeloid Leukemia

    Hugo F. Fernandez;Zhuoxin Sun;Xiaopan Yao;Mark R. Litzow

  • Establishment of an immature mast cell line from a patient with mast cell leukemia.

    J. H. Butterfield;D. Weiler;G. Dewald;Gerald J. Gleich

  • Clinical and biologic implications of recurrent genomic aberrations in myeloma

    Rafael Fonseca;Emily Blood;Montserrat Rue;David Harrington

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

    Anthony V. Moorman;Christine J. Harrison;Georgina A.N. Buck;Sue M. Richards

  • The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

    David P. Steensma;David P. Steensma;Gordon W. Dewald;Gordon W. Dewald;Terra L. Lasho;Terra L. Lasho;Heather L. Powell;Heather L. Powell

  • Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

    Azra Raza;James A. Reeves;Eric J. Feldman;Gordon W. Dewald

  • The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis

    Gordon W. Dewald;Robert A. Kyle;Gary A. Hicks;Philip R. Greipp

  • Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997

    Ian W. Flinn;Donna S. Neuberg;Michael R. Grever;Gordon W. Dewald

  • Genomic abnormalities in monoclonal gammopathy of undetermined significance

    Rafael Fonseca;Richard J. Bailey;Gregory J. Ahmann;S. Vincent Rajkumar

  • Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997

    Michael R. Grever;David M. Lucas;Gordon W. Dewald;Donna S. Neuberg

  • CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

    Animesh Pardanani;Animesh Pardanani;Animesh Pardanani;Rhett P. Ketterling;Rhett P. Ketterling;Rhett P. Ketterling;Stephanie R. Brockman;Stephanie R. Brockman;Stephanie R. Brockman;Heather C. Flynn;Heather C. Flynn;Heather C. Flynn

  • T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

    David I. Marks;Elisabeth M. Paietta;Anthony V. Moorman;Susan M. Richards

  • Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

    Yaping Shou;Maria L. Martelli;Ana Gabrea;Ying Qi

  • Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

    Neil E. Kay;Susan M. Geyer;Timothy G. Call;Tait D. Shanafelt

  • The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

    Rafael Fonseca;Carina S. Debes-Marun;Elisa B. Picken;Gordon W. Dewald

  • FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.

    Animesh Pardanani;Stephanie R. Brockman;Sarah F. Paternoster;Heather C. Flynn

  • Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

    Rafael Fonseca;Emily A. Blood;Emily A. Blood;Martin M. Oken;Martin M. Oken;Robert A. Kyle;Robert A. Kyle

  • A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

    Jacob M. Rowe;Donna Neuberg;William Friedenberg;John M. Bennett

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia

    A Moorman;C J Harrison;Buck Gan.;S M Richards

Frequent Co-Authors

Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Neil E. Kay
Neil E. Kay Mayo Clinic
Jacob M. Rowe
Jacob M. Rowe Technion – Israel Institute of Technology
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Curtis A. Hanson
Curtis A. Hanson Mayo Clinic
John M. Bennett
John M. Bennett University of Rochester Medical Center
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Tait D. Shanafelt
Tait D. Shanafelt Stanford University
Donna Neuberg
Donna Neuberg Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Genetics opens doors to a variety of rewarding careers in healthcare and the sciences. For many students, online programs can be an accessible pathway to advanced roles. There are several related fields to consider if you want flexibility or a broader perspective.

Those interested in nursing may benefit from nursing schools that do not require entrance exam requirements, making it easier to begin a healthcare career. For further progression, professionals can find the cheapest online nursing phd programs to boost credentials without a large financial burden.

If quick entry into the workforce is your goal, there are fast track medical programs available online that shorten the timeline to becoming a Licensed Practical Nurse (LPN). For those aiming for healthcare administration roles, you can also review the most affordable mha programs that prepare graduates for leadership positions in the medical field.

Each of these pathways complements a background in Genetics and can enhance your career opportunities in the expanding landscape of health sciences.

Best Scientists Citing Gordon W. Dewald

Recently Published Articles